DaVita (NYSE:DVA) Price Target Raised to $235.00

DaVita (NYSE:DVA) had its price target upped by UBS Group from $190.00 to $235.00 in a research report report published on Thursday,Benzinga reports. They currently have a buy rating on the stock.

DVA has been the subject of a number of other research reports. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Wall Street Zen raised shares of DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Barclays raised their price target on shares of DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a report on Thursday. Deutsche Bank Aktiengesellschaft raised shares of DaVita from a “hold” rating to a “buy” rating and raised their price target for the company from $126.00 to $220.00 in a report on Wednesday. Finally, Truist Financial set a $158.00 price target on shares of DaVita in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $187.83.

DaVita Trading Up 1.1%

NYSE:DVA opened at $198.39 on Thursday. DaVita has a 1 year low of $101.00 and a 1 year high of $199.27. The firm has a 50 day moving average of $153.03 and a 200-day moving average of $132.70. The stock has a market capitalization of $12.74 billion, a P/E ratio of 18.40, a price-to-earnings-growth ratio of 0.65 and a beta of 0.84.

DaVita (NYSE:DVA) last posted its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.36 billion. During the same quarter in the previous year, the company posted $2.00 earnings per share. DaVita’s quarterly revenue was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts forecast that DaVita will post 15.07 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

A number of hedge funds and other institutional investors have recently made changes to their positions in DVA. Root Financial Partners LLC lifted its position in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after acquiring an additional 105 shares in the last quarter. Elevation Wealth Partners LLC lifted its position in DaVita by 147.3% in the 4th quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after acquiring an additional 165 shares in the last quarter. Caitlin John LLC bought a new stake in DaVita in the 4th quarter valued at $34,000. Sankala Group LLC bought a new stake in DaVita in the 4th quarter valued at $39,000. Finally, Canada Pension Plan Investment Board bought a new stake in DaVita in the 2nd quarter valued at $43,000. 90.12% of the stock is owned by institutional investors.

Key Stories Impacting DaVita

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: DaVita reported Q1 results that topped expectations, with adjusted EPS of $2.87 versus consensus near $2.33 and revenue of $3.42 billion above estimates. The company also lifted its 2026 EPS guidance, reinforcing confidence in the earnings outlook. DaVita (DVA) Is Up 27.6% After Boosting 2026 EPS Guidance On Strong Q1 Results
• Positive Sentiment: UBS raised its price target on DaVita to $235 from $190 and kept a Buy rating, signaling further upside potential after the post-earnings rally. UBS Group Issues Positive Forecast for DaVita (NYSE:DVA) Stock Price
• Positive Sentiment: Multiple Zacks articles highlighted DaVita as a Strong Buy value stock and pointed to improving earnings estimate revisions, which can attract momentum and value investors. Surging Earnings Estimates Signal Upside for DaVita HealthCare (DVA) Stock
• Positive Sentiment: Seeking Alpha said DaVita was upgraded to Buy after strong Q1 results, improved volumes, and a favorable valuation profile, supporting the case that the stock can continue to outperform. DaVita: Improved Volumes And Tech In Focus (Rating Upgrade)
• Neutral Sentiment: DaVita also announced participation in the BofA Securities 2026 Health Care Conference, which may keep the company in front of investors but is not a direct operating catalyst. DaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.